Former Major Shareholder Sells $306K in KALA BIO Stock, Reduces Stake Below 5%

summarizeSummary

A former major investor in KALA BIO, David E. Lazar, sold over $300,000 worth of shares, reducing his stake below 5% following the company's recent reverse stock split and shelf registration.

check_boxKey Events · Ownership and Investor Activity · KALA

• Significant Share Sales

  David E. Lazar sold 106,732 shares of common stock for total proceeds of approximately $306,564 across multiple transactions between May 4 and June 29, 2026. These sales represent a substantial portion of the company's market capitalization.

• Reduced Ownership Below 5%

  The reporting person ceased to be a beneficial owner of more than 5% of KALA BIO's outstanding shares as of April 24, 2026, and has continued to reduce his stake through subsequent sales.

• Post-Split Transactions

  All reported share numbers and prices in the transaction history are explicitly stated to be adjusted for the 1-for-50 reverse stock split effected by the Issuer on May 8, 2026.

• Cost Basis of Remaining Shares

  The aggregate purchase price for the 719,404 shares currently held by Lazar (converted from Series AA Preferred Stock) was $1,308,007, implying an average cost of approximately $1.82 per share.

auto_awesomeAnalysis · KALA · Life Sciences

David E. Lazar, a former significant shareholder, has disclosed selling approximately $306,564 worth of KALA BIO common stock across multiple transactions between May and June 2026. These sales represent nearly 1% of the company's market capitalization and follow his cessation of beneficial ownership above 5% in April 2026. The continued reduction of his stake, particularly after the recent 1-for-50 reverse stock split and shelf registration, and while the stock is trading near its 52-week lows, indicates a lack of conviction from a major investor.